DE69941429D1 - 1-deoxy-galactonojirimycin-derivate zur vewendung bei der behandlung von lysosomalen speicherkrankheiten mittels steigerung der lysosomalen alpha galactosidase a - Google Patents

1-deoxy-galactonojirimycin-derivate zur vewendung bei der behandlung von lysosomalen speicherkrankheiten mittels steigerung der lysosomalen alpha galactosidase a

Info

Publication number
DE69941429D1
DE69941429D1 DE69941429T DE69941429T DE69941429D1 DE 69941429 D1 DE69941429 D1 DE 69941429D1 DE 69941429 T DE69941429 T DE 69941429T DE 69941429 T DE69941429 T DE 69941429T DE 69941429 D1 DE69941429 D1 DE 69941429D1
Authority
DE
Germany
Prior art keywords
lysosomal
deoxy
treatment
jirimycin
galactono
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69941429T
Other languages
English (en)
Inventor
Jian-Qiang Fan
Satoshi Ishii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Mount Sinai School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai School of Medicine filed Critical Mount Sinai School of Medicine
Application granted granted Critical
Publication of DE69941429D1 publication Critical patent/DE69941429D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
DE69941429T 1998-06-01 1999-05-28 1-deoxy-galactonojirimycin-derivate zur vewendung bei der behandlung von lysosomalen speicherkrankheiten mittels steigerung der lysosomalen alpha galactosidase a Expired - Lifetime DE69941429D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/087,804 US6274597B1 (en) 1998-06-01 1998-06-01 Method of enhancing lysosomal α-Galactosidase A
PCT/US1999/010479 WO1999062517A1 (en) 1998-06-01 1999-05-28 METHOD OF ENHANCING LYSOSOMAL α-GALACTOSIDASE A

Publications (1)

Publication Number Publication Date
DE69941429D1 true DE69941429D1 (de) 2009-10-29

Family

ID=22207362

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69941429T Expired - Lifetime DE69941429D1 (de) 1998-06-01 1999-05-28 1-deoxy-galactonojirimycin-derivate zur vewendung bei der behandlung von lysosomalen speicherkrankheiten mittels steigerung der lysosomalen alpha galactosidase a

Country Status (12)

Country Link
US (16) US6274597B1 (de)
EP (2) EP1083899B1 (de)
JP (2) JP4602548B2 (de)
AT (1) ATE442851T1 (de)
AU (1) AU4186199A (de)
CA (1) CA2333965C (de)
CY (2) CY1112845T1 (de)
DE (1) DE69941429D1 (de)
DK (2) DK2143420T3 (de)
ES (2) ES2507515T3 (de)
PT (2) PT1083899E (de)
WO (1) WO1999062517A1 (de)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US20050032841A1 (en) * 1999-04-20 2005-02-10 Steven Walkley Therapeutic compositions and methods of treating glycolipid storage related disorders
DE60138535D1 (de) * 2000-02-04 2009-06-10 Children S Hospital Res Founda Verwendung von lysosomal acid lipase zur behandlung von atherosklerose und ähnlichen krankheiten
AU2002328402B2 (en) * 2001-09-07 2008-06-12 Seikagaku Corporation Carba-sugar amine derivatives and treatments for disorder of glycolipid metabolism containing the same as the active ingredient
US7842470B2 (en) * 2001-10-09 2010-11-30 Oregon Health & Science University Method for pharmacoperones correction of GnRHR mutant protein misfolding
WO2004004740A1 (en) * 2002-07-05 2004-01-15 King Roderick Frederick Gerard Aqueous formulation comprising digestible saccharides to reduce the tendency to cardiovascular disease in a subject
AU2003284886A1 (en) * 2002-10-21 2004-05-13 William E. Balch CHEMICAL CHAPERONES AND THEIR EFFECT UPON THE CELLULAR ACTIVITY OF Beta-GLUCOSIDASE
CA2814767C (en) * 2003-01-31 2016-03-15 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiency disorders
US7446098B2 (en) * 2003-02-18 2008-11-04 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiencies
EP1633356A1 (de) * 2003-05-22 2006-03-15 The Hospital for Sick Children Behandlung von tay sachs oder sandhoff erkrankungen durch erhöhung der hexosaminidase aktivität
FR2861991B1 (fr) 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
EP1682504B1 (de) * 2003-11-12 2012-12-26 Amicus Therapeutics Inc. Hydroxypiperidinderivate zur behandlung von gaucher-krankheit
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
CA2507348C (en) * 2004-05-13 2013-07-16 The Hospital For Sick Children Real time methylumbelliferone-based assay
US20090239807A1 (en) * 2004-05-24 2009-09-24 Mia Horowitz Methods and kits for diagnosing and/or assessing severity and treating gaucher disease
JP2008503590A (ja) * 2004-06-21 2008-02-07 メドトロニック・インコーポレーテッド 組成物を細胞にデリバリーするための医学用システム及び方法
WO2006007560A2 (en) * 2004-07-01 2006-01-19 University Of Pennsylvania Targeted protein replacement for the treatment of lysosomal storage disorders
FR2873377B1 (fr) * 2004-07-23 2006-10-13 Sanofi Synthelabo Derives d'azasucre, inhibiteurs d'heparanases, leur procede de preparation, les compositions en contenant et leur utilisation
KR20080025373A (ko) 2005-05-17 2008-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 1-데옥시노지리마이신 및 유도체를 이용한 폼페병의 치료방법
US20070021433A1 (en) * 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
ES2485369T3 (es) * 2005-06-08 2014-08-13 Amicus Therapeutics, Inc. Tratamiento de trastornos del SNC asociados con mutaciones en genes que codifican enzimas lisosómicas
FR2887549B1 (fr) * 2005-06-23 2009-07-10 Centre Nat Rech Scient Nouveaux composes de la famille des iminosucres, leurs utilisations, notamment pour le traitement de maladies lysosomales, ainsi que leur procede de preparation
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
EP2787345B8 (de) 2006-05-16 2016-04-13 Amicus Therapeutics, Inc. Behandlungsoptionen für morbus fabry
AU2013205532B8 (en) * 2006-05-16 2015-07-16 Amicus Therapeutics, Inc. Assays for diagnosing and evaluating treatment options for fabry disease
AU2015230773B2 (en) * 2006-05-16 2017-09-28 Amicus Therapeutics Inc. Assays for diagnosing and evaluating treatment options for fabry disease
ATE504570T1 (de) * 2006-05-24 2011-04-15 Amicus Therapeutics Inc Tartratsalz aus isofagomin und verwendungsverfahren dafür
ES2364586T3 (es) * 2006-05-24 2011-09-07 Amicus Therapeutics, Inc. Sal tartrato de isofagomina y métodos de uso.
MX2009000032A (es) * 2006-06-23 2009-01-23 Amicus Therapeutics Inc Metodo para el tratamiento de trastornos neurologicos por la mejora de la actividad de la beta-glucocerebrosidasa.
EP2399587A1 (de) * 2006-08-02 2011-12-28 The University of Oxford Liposomenbehandlung von Virusinfektionen
US20100144008A1 (en) * 2006-12-21 2010-06-10 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of fabry disease
WO2008112525A2 (en) * 2007-03-09 2008-09-18 Link Medicine Corporation Treatment of lysosomal storage diseases
MX2009010557A (es) * 2007-03-30 2009-11-19 Amicus Therapeutics Inc Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas.
US20100197018A1 (en) * 2007-04-13 2010-08-05 Amicus Therapeutics, Inc. Use of substrates as pharmacological chaperones
JP5586453B2 (ja) * 2007-04-13 2014-09-10 アミカス セラピューティックス インコーポレイテッド 特異的薬理シャペロンによるゴーシェ病の治療および代理マーカーを用いた治療の監視
US9999618B2 (en) 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
CA2685332A1 (en) * 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
AU2008254594B2 (en) 2007-05-22 2013-06-27 Amicus Therapeutics, Inc. New method for preparing isofagomine and its derivatives
WO2009049421A1 (en) * 2007-10-18 2009-04-23 The Hospital For Sick Children Compositions and methods for enhancing enzyme activity in gaucher, gm1-gangliosidosis/morquio b disease, and parkinson's disease
US20100317690A1 (en) * 2007-11-21 2010-12-16 Summit Corporation Plc Treatment of protein folding disorders
SI3470077T1 (sl) 2008-02-12 2020-12-31 Amicus Therapeutics, Inc. Postopek za napovedovanje odgovora na zdravljenje bolezni s farmakološkim spremljevalcem
EP2282723A2 (de) * 2008-03-26 2011-02-16 University of Oxford Liposome mit endoplasmischem retikulum als target
PL2659904T3 (pl) 2008-06-26 2016-01-29 Orphazyme Aps Zastosowanie Hsp70 jako regulatora aktywności enzymatycznej
WO2010048532A1 (en) * 2008-10-24 2010-04-29 Amicus Therapeutics, Inc. Multiple compartment dosing model
WO2010056746A1 (en) * 2008-11-11 2010-05-20 Amicus Therapeutics, Inc. Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
CN102427804A (zh) * 2009-03-27 2012-04-25 牛津大学之校长及学者 降低胆固醇水平的脂质体
GB0906159D0 (en) * 2009-04-09 2009-05-20 Summit Corp Plc Drug combination for the treatment of proteostatic diseases
US20110070643A1 (en) * 2009-05-26 2011-03-24 Do Hung V Utilization of Pharmacological Chaperones to Improve Manufacturing and Purification of Biologics
US9206457B2 (en) * 2009-05-26 2015-12-08 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
AR078498A1 (es) * 2009-10-01 2011-11-09 Baylor Res Inst Tratamiento de calvicie de patron masculino por induccion local del defecto metabolico de la enfermedad de fabry
JP5805649B2 (ja) * 2009-10-19 2015-11-04 アミカス セラピューティックス インコーポレイテッド 中枢神経系の変性障害を予防および／または治療するための新規の組成物
EP2490712B1 (de) 2009-10-19 2015-07-08 Amicus Therapeutics, Inc. Verfahren zur behandlung von morbus alzheimer mit pharmakologischen chaperonen zur erhöhung der aktivität von gangliosidasen
RU2016103139A (ru) 2009-10-19 2018-11-22 Амикус Терапьютикс, Инк. Новые композиции для предупреждения и/или лечения лизосомных болезней накопления
US9194011B2 (en) * 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
KR101784539B1 (ko) * 2010-01-28 2017-10-11 랩터 파마슈티컬스 인코포레이티드 수용체 결합 단백질(ｒａｐ) 펩타이드-푸코시다제 억제제 접합체를 이용한 간 질환의 치료방법
KR20130009751A (ko) * 2010-02-02 2013-01-23 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 Ｄ-글루쿠로노락톤으로부터 ＤＧＪＮＡｃ의 합성 및 알파-Ｎ-아세틸갈락토사미니다제를 억제하기 위한 용도
PL2646044T3 (pl) 2010-11-30 2020-03-31 Orphazyme A/S Sposoby zwiększenia aktywności wewnątrzkomórkowej Hsp70
AU2012229330B2 (en) * 2011-03-11 2016-04-21 Amicus Therapeutics, Inc. Dosing regimens for the treatment of Fabry disease
US10350277B2 (en) 2011-09-07 2019-07-16 Icahn School Of Medicine At Mount Sinai Ceramidase and cell differentiation
WO2013079580A1 (en) 2011-11-29 2013-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of darier disease
JP6236406B2 (ja) 2012-03-07 2017-11-22 アミカス セラピューティックス インコーポレイテッド ポンペ病の処置のための高濃度α−グルコシダーゼ組成物
EP2854910B1 (de) 2012-06-01 2020-04-15 Icahn School of Medicine at Mount Sinai Ceramidspiegel bei der behandlung und vorbeugung von infektionen
AU2014205378B2 (en) 2013-01-09 2018-08-30 Amicus Therapeutics, Inc. Stable parenteral DNJ compositions
ES2739811T3 (es) 2013-03-14 2020-02-04 Icahn School Med Mount Sinai Composiciones terapéuticas de ceramidasa ácida y métodos de fabricación y uso de ellas
US9675627B2 (en) 2014-04-14 2017-06-13 Amicus Therapeutics, Inc. Dosing regimens for treating and/or preventing cerebral amyloidoses
JP6678676B2 (ja) 2014-09-15 2020-04-08 オーファザイム エー／エス アリモクロモル製剤
PT3201320T (pt) 2014-09-30 2024-01-12 Amicus Therapeutics Inc Alfa-glucosidase ácida altamente potente com hidratos de carbono intensificados
CN110141399B (zh) 2015-02-05 2021-07-27 卡迪尔维尔福股份有限公司 带有轴向滑动框架的人工瓣膜
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
KR102510941B1 (ko) 2015-12-30 2023-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
JP7098529B2 (ja) 2016-03-22 2022-07-11 アミカス セラピューティックス インコーポレイテッド Ｇｌａ遺伝子にｇ９３３１ａ変異を有する患者においてファブリー病を処置する方法
KR102343162B1 (ko) 2016-03-30 2021-12-23 아미쿠스 세라퓨틱스, 인코포레이티드 고 m6p 재조합 단백질의 선택 방법
KR102618519B1 (ko) 2016-03-30 2023-12-28 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
EP3448382B1 (de) 2016-04-29 2020-10-14 Orphazyme A/S Arimoclomol zur behandlung mit glucocerebrosidase assoziierten störungen
US20190183869A1 (en) 2016-07-19 2019-06-20 Amicus Therapeutics, Inc. Treatment of fabry disease in ert-naïve and ert-experienced patients
NL2017294B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Natural cryptic exon removal by pairs of antisense oligonucleotides.
JP2020507562A (ja) 2017-05-30 2020-03-12 アミカス セラピューティックス インコーポレイテッド 腎機能障害を有するファブリー患者の治療方法
EP4245366A3 (de) 2017-05-30 2023-11-29 Amicus Therapeutics, Inc. Migalastat zur behandlung von nierenbeeinträchtigten patienten mit morbus fabry
UA125938C2 (uk) 2017-06-01 2022-07-13 Ідорсія Фармасьютікалз Лтд Кристалічна форма n-бутилдеоксигалактоноджириміцину
JP7066157B2 (ja) * 2017-06-14 2022-05-13 学校法人 明治薬科大学 ファブリー病治療用医薬の組合せ物及びその利用
WO2019017938A1 (en) 2017-07-19 2019-01-24 Amicus Therapeutics, Inc. TREATMENT OF FABRY'S DISEASE IN PATIENTS WITHOUT SUBSTITUTED ENZYMATIC THERAPY (TES) AND PATIENTS SUBJECT TO TES
KR20200044908A (ko) 2017-08-28 2020-04-29 아미쿠스 세라퓨틱스, 인코포레이티드 파브리병을 앓는 환자에서 심장 기능을 강화 및/또는 안정화시키는 방법
US20200206323A1 (en) * 2017-09-08 2020-07-02 The Nemours Foundation An agent, a device and a blood-circulation system for treating lysosomal storage diseases, and a method for treating lysosomal storage diseases
US10856972B2 (en) 2017-09-19 2020-12-08 Cardiovalve Ltd. Prosthetic valve with angularly offset atrial anchoring arms and ventricular anchoring legs
CN107699590A (zh) * 2017-10-13 2018-02-16 成都中医药大学 一种制备重组人α‑L‑艾杜糖醛酸酶的方法
ES2716305B2 (es) 2017-12-11 2019-11-27 Fund Biomedica Galicia Sur Uso de chaperonas farmacologicas para el tratamiento de enfermedades de deposito lisosomal
US11357784B2 (en) 2018-02-06 2022-06-14 Amicus Therapeutics, Inc. Use of migalastat for treating Fabry disease in pregnant patients
FI3749308T3 (fi) 2018-02-06 2024-01-18 Amicus Therapeutics Inc Potilaiden, joilla on klassinen fabryn tauti, hoito migalastaatilla
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
EP3840753A1 (de) 2018-08-20 2021-06-30 Amicus Therapeutics, Inc. Verfahren zur behandlung von morbus fabry bei patienten mit einer mutation in dem gla-gen
TW202042812A (zh) 2019-01-22 2020-12-01 美商阿米庫斯醫療股份有限公司 減少法布瑞氏症患者中之腦血管事件之方法
CN114423427A (zh) 2019-06-11 2022-04-29 阿米库斯治疗学公司 治疗具有肾损害的患者的法布里病的方法
CN114423428A (zh) 2019-08-07 2022-04-29 阿米库斯治疗学公司 治疗在gla基因中具有突变的患者的法布里病的方法
JP2022548162A (ja) * 2019-10-04 2022-11-16 アカデミア シニカ ポンペ病を処置する方法
EP4065395A4 (de) * 2019-11-27 2024-02-14 Turning Point Therapeutics Inc Kombinationstherapie mit diarylmakrocyclischen verbindungen
AU2021218578A1 (en) * 2020-02-10 2022-08-25 Amicus Therapeutics, Inc. Methods of treating Fabry disease
EP4114390A1 (de) 2020-03-06 2023-01-11 Amicus Therapeutics, Inc. Verfahren zur behandlung von morbus fabry bei patienten mit einer mutation im gla-gen
US20230416224A1 (en) 2020-11-19 2023-12-28 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
KR20240034203A (ko) 2021-07-12 2024-03-13 아미쿠스 세라퓨틱스, 인코포레이티드 소아청소년 환자에서 파브리병을 치료하는 방법
WO2023060233A1 (en) 2021-10-08 2023-04-13 Amicus Therapeutics, Inc. Biomarkers for lysosomal storage diseases

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
JPS61280472A (ja) 1985-06-05 1986-12-11 Shionogi & Co Ltd β−ガラクトシダ−ゼ阻害物質ガラクトスタチン類およびその製造方法
EP0252962B1 (de) 1985-12-23 1995-08-23 Fred Hutchinson Cancer Research Center Regulierung der retroviralen replikation, infektion und pathogenese
DE3737523A1 (de) 1987-11-05 1989-05-18 Bayer Ag Verwendung von substituierten hydroxypiperidinen als antivirale mittel
US5192772A (en) 1987-12-09 1993-03-09 Nippon Shinyaku Co. Ltd. Therapeutic agents
US5250545A (en) 1988-02-12 1993-10-05 Meiji Seika Kaisha, Ltd. Cancer cell metastasis inhibitor methods
FR2640621B1 (fr) 1988-12-19 1992-10-30 Centre Nat Rech Scient N-aryl-azetidinones, leur procede de preparation et leur utilisation comme inhibiteurs des elastases
US5043273A (en) 1989-08-17 1991-08-27 Monsanto Company Phosphorylated glycosidase inhibitor prodrugs
US5030638A (en) 1990-02-26 1991-07-09 G. D. Searle & Co. Method of antiviral enhancement
US5504078A (en) 1990-06-08 1996-04-02 Merrell Dow Pharmaceuticals Inc. α-glucosidase inhibitors
EP0536402A4 (en) 1990-06-29 1993-05-12 Nippon Shinyaku Company, Limited Piperidine derivative
US5276120A (en) 1991-05-30 1994-01-04 The Scripps Research Institute Process for forming omega-deuxy-azasugars
US6291657B1 (en) 1993-05-13 2001-09-18 Monsanto Company Deoxygalactonojirimycin derivatives
US5798366A (en) * 1993-05-13 1998-08-25 Monsanto Company Method for treatment of CNS-involved lysosomal storage diseases
US5399567A (en) * 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
JPH0748398A (ja) 1993-08-03 1995-02-21 Nippon Oil Co Ltd 変性蛋白質の再生方法及び変性蛋白質再生剤
US5691306A (en) 1993-08-26 1997-11-25 National Research Council Of Canada Methods of detection and treatment of protein trafficking disorders and increasing secretory protein production
AU1403795A (en) 1994-01-13 1995-08-01 G.D. Searle & Co. Use of n-alkyl derivatives of 1,5-dideoxy-1,5-imino-d-glucitol for the treatment of hepatitis b virus infections
AU1876095A (en) 1994-02-25 1995-09-11 G.D. Searle & Co. Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus
US5863903A (en) 1994-03-09 1999-01-26 Novo Nordisk A/S Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
US5844102A (en) 1994-07-07 1998-12-01 University Of Maryland Baltimore County Glycohydrolase inhibitors, their preparation and use thereof
CA2260790C (en) 1996-07-15 2007-01-09 Universiteit Van Amsterdam Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors
KR20050084473A (ko) 1996-09-13 2005-08-26 트랜스케리오틱 쎄러피스, 인코포레이티드 α-갈락토시다아제 Ａ 결핍을 치료하는 방법
GB9700233D0 (en) 1997-01-08 1997-02-26 Univ London Use of glycosidase inhibitors
US6210666B1 (en) * 1997-10-21 2001-04-03 Orphan Medical, Inc. Truncated α-galactosidase A to treat fabry disease
AU753336B2 (en) 1997-11-10 2002-10-17 G.D. Searle & Co. Use of alkylated iminosugars to treat multidrug resistance
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
WO1999040435A1 (en) 1998-02-09 1999-08-12 Netzer William J Protein folding inhibitors
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
AU1734600A (en) 1998-11-17 2000-06-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Identification of glycosphingolipids that promote hiv-1 entry into cells
OA11722A (en) 1998-12-02 2005-01-25 Pfizer Prod Inc Methods and compositions for restoring conformational stability of a protein of the p53 family.
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
JP2000219632A (ja) 1999-01-28 2000-08-08 Toyotama Koryo Kk カロリー軽減剤
WO2000056334A1 (en) 1999-03-19 2000-09-28 The Trustees Of Boston College Use of imino sugars for anti-tumor therapy
CA2306039A1 (en) 1999-04-19 2000-10-19 Schering Corporation Hcv combination therapy
GB9909064D0 (en) 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
US6476194B1 (en) 1999-06-29 2002-11-05 National Research Council Of Canada Method for folding unfolded proteins
EP1196190B1 (de) 1999-07-26 2003-03-19 G.D. SEARLE &amp; CO. Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin mit glucocerebrosidase enzyme zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten
JP2003506406A (ja) 1999-08-10 2003-02-18 ザ・チャンセラー・マスターズ・アンド・スカラーズ・オブ・ザ・ユニバーシティ・オブ・オックスフォード 長鎖ｎ−アルキル化合物およびそのオキサ誘導体
WO2001021652A1 (en) 1999-09-24 2001-03-29 The Johns Hopkins University School Of Medicine Methods for identifying an agent that corrects defective protein folding
EP1250129A2 (de) 2000-01-20 2002-10-23 Washington University Verfahren zur behandlung von g(a)-1-antitrypsinmangel
WO2001097829A2 (en) 2000-06-19 2001-12-27 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20020115619A1 (en) 2000-10-04 2002-08-22 Rubenstein Ronald C. Compositions and methods for treatment of cystic fibrosis
JP2002190202A (ja) 2000-10-12 2002-07-05 Koito Mfg Co Ltd ヘッドランプ
JP3589449B2 (ja) 2001-02-26 2004-11-17 株式会社ユニレック 静電容量センサ、管内流動判断装置、管内流動制御装置
JP4802548B2 (ja) * 2005-04-28 2011-10-26 シンフォニアテクノロジー株式会社 Ｉｃチップ実装体の製造装置
US7174582B1 (en) * 2005-08-17 2007-02-13 Kevin J Leary Crib mattress bouncer
BRPI0908438A2 (pt) 2008-02-14 2015-12-08 Signum Biosciences Inc composto miméticos de acetila para inibição de transferase de metil isoprenil-s-cisteinila
ES2549158T3 (es) 2008-11-11 2015-10-23 Signum Biosciences, Inc. Compuestos de isoprenilo y métodos de los mismos
WO2010090845A1 (en) 2009-01-20 2010-08-12 Signum Biosciences, Inc. Anti-inflammatory complexes

Also Published As

Publication number Publication date
US7622485B2 (en) 2009-11-24
AU4186199A (en) 1999-12-20
US7812033B2 (en) 2010-10-12
EP2143420A1 (de) 2010-01-13
US20110076765A1 (en) 2011-03-31
US20020156100A1 (en) 2002-10-24
US20030119874A1 (en) 2003-06-26
JP5528941B2 (ja) 2014-06-25
US9265780B2 (en) 2016-02-23
US20100137229A1 (en) 2010-06-03
JP2003528799A (ja) 2003-09-30
US8841322B2 (en) 2014-09-23
DK2143420T3 (da) 2014-10-06
ATE442851T1 (de) 2009-10-15
US20020198225A1 (en) 2002-12-26
US20160346262A1 (en) 2016-12-01
US20040242539A1 (en) 2004-12-02
EP1083899A1 (de) 2001-03-21
US20140206718A1 (en) 2014-07-24
US20140051725A1 (en) 2014-02-20
WO1999062517A1 (en) 1999-12-09
DK1083899T3 (da) 2010-01-25
US6274597B1 (en) 2001-08-14
US6774135B2 (en) 2004-08-10
US8633221B2 (en) 2014-01-21
US20050113415A1 (en) 2005-05-26
US20020035072A1 (en) 2002-03-21
CA2333965C (en) 2011-03-22
JP2010270146A (ja) 2010-12-02
CY1112845T1 (el) 2016-02-10
EP1083899A4 (de) 2004-11-03
PT2143420E (pt) 2014-09-30
ES2333561T3 (es) 2010-02-23
ES2507515T3 (es) 2014-10-15
EP1083899B1 (de) 2009-09-16
US8436018B2 (en) 2013-05-07
PT1083899E (pt) 2009-12-18
US6583158B1 (en) 2003-06-24
US6599919B2 (en) 2003-07-29
JP4602548B2 (ja) 2010-12-22
CA2333965A1 (en) 1999-12-09
US20070021381A1 (en) 2007-01-25
CY1115583T1 (el) 2017-01-04
US20150258129A1 (en) 2015-09-17
US6589964B2 (en) 2003-07-08
US7514453B2 (en) 2009-04-07
EP2143420B1 (de) 2014-06-25
US7141582B2 (en) 2006-11-28
US6916829B2 (en) 2005-07-12
US20060100241A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
DE69941429D1 (de) 1-deoxy-galactonojirimycin-derivate zur vewendung bei der behandlung von lysosomalen speicherkrankheiten mittels steigerung der lysosomalen alpha galactosidase a
EE03523B1 (et) Fenantridiinid, neid sisaldavad ravimid ja nende kasutamine
TR200101793T2 (tr) CCR5 modülatörleri olarak azabisikloalkanlar
MX9803753A (es) Acidos alfa-iminohidroxamicos y -carboxilicos n-sustituidos ciclicos y heterociclicos.
ES2191192T3 (es) Tienopirimidinas.
TR199800818A2 (xx) �kame edilmi� diaminokarbonik asitler.
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
TR200200938T2 (tr) CCR5 modülatörleri olarak piperidinler
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
TR200103493T2 (tr) Metaloproteaz önleyicileri
ATE423208T1 (de) Oberflächenlokalisierte expression von enzymen in gengesteuerter prodrugtherapie
ES2184077T3 (es) Nuevas fenantridinas sustituidas en la posicion 6.
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
DE69718169D1 (de) Test zur diagnose von schizophrenie mittels niacin
DE69625918D1 (de) Lang wirksames mittel zur rektalen verabreichung
DK2359853T3 (da) Farmaceutiske sammensætninger og fremgangsmåder, der er anvendelige til at modulere antiogenese
DE60022879D1 (de) Reporterverbindungen und verfahren zur auffindung von hochspezifische proteaseaktivität
TR199901385T2 (xx) Piperidin t�revleri.
ATE222103T1 (de) Inklusionskomplexe in waessriger loesung
DE69113437D1 (de) Therapeutische Mittel für diabetisches Gangrän.
ES2181160T3 (es) Derivados de 1,4-dihidropiridina y su utilizacion en terapia.
DE69825307D1 (de) Verwendung von protein h als zytostattischer wirkstoff
NO870398L (no) Fremgangsmaate for fremstilling av terapeutisk aktive organiske platinakomplekser.
ATE297745T1 (de) Chemische modifizierung von harn von säugern

Legal Events

Date Code Title Description
8364 No opposition during term of opposition